Psychosocial issues and mental health treatment recommendations for patients with hepatitis C

Psychosomatics

Volumn 50, Issue 2, 2009, Pages 114-122

  Silberbogen, Amy K ^a   Ulloa, Erin W ^b   Janke, Amy ^b   Mori, De Anna L ^b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ADJUSTMENT; ALCOHOL CONSUMPTION; ANXIETY; COGNITIVE THERAPY; COPING BEHAVIOR; DEPRESSION; DIARRHEA; EDUCATION; EXERCISE; FATIGUE; FLU LIKE SYNDROME; HEADACHE; HEPATITIS C; HUMAN; IRRITABILITY; LIFESTYLE MODIFICATION; LIVER INJURY; MENTAL HEALTH CARE; MENTAL HEALTH CARE PERSONNEL; NAUSEA; NUTRITION; PAIN; PATIENT CARE; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REVIEW; SEXUAL TRANSMISSION; SIDE EFFECT; SMOKING; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; STRESS MANAGEMENT;

EID: 66749185861     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.2.114     Document Type: Review

References (98)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al: The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-562
2. Terrault NA: Hepatitis C virus and liver transplantation. Semin Gastrointest Dis 2000; 11:96-114
3. Strader DB, Wright T, Thomas DL, et al: Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39:1147-1171
4. Detre KM, Belle SH, Lombardero M: Liver transplantation for chronic viral hepatitis. Viral Hepatitis Review 1996; 2:219-228
5. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C: the OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832
6. Seeff LB, Hoofnagle JH: NIH Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology 2002; 36:S1-S2
7. Hourigan LF, Macdonald GA, Purdie D, et al: Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999; 29:1215-1219
8. Corrao G, Arico S: Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology 1998; 27:914-919
9. Manns MP, McHutchison JG, Gordon SC, et al: Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus riba- virin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965
10. Crone C, Gabriel GM: Comprehensive review of hepatitis C for psychiatrists: risks, screening, diagnosis, treatment, and inter- feron-based therapy complications. J Psychiatr Pract 2003; 9:93-110
11. Dieperink E, Willenbring M, Ho SB: Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000; 157:867-876
12. Lee DH, Jamal H, Regenstein FG, et al: Morbidity of chronic hepatitis C as seen in a tertiary-care medical center. Dig Dis Sci 1997; 42:186-191
13. McHutchison JG, Gordon SC, Schiff ER, et al: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C: Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-1492
14. Fontana RJ, Schwartz SM, Gebremariam A, et al: Emotional distress during interferon-alpha-2B and ribavirin treatment of chronic hepatitis C. Psychosomatics 2002; 43:378-385
15. Kraus MR, Schafer A, Faller H, et al: Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry 2003; 64:708-714
16. el-Serag HB, Kunik M, Richardson P, et al: Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology 2002; 123:476-482
17. Ho SB, Nguyen H, Tetrick LL, et al: Influence of psychiatric diagnoses on interferon-alpha treatment for chronic hepatitis C in a veteran population. Am J Gastroenterol 2001; 96:157-164
18. Muir AJ, Provenzale D: A descriptive evaluation of eligibility for therapy among veterans with chronic hepatitis C. J Clin Gastroenterol 2002; 34:268-271
19. Lehman CL, Cheung RC: Depression, anxiety, post-traumatic stress, and alcohol-related problems among veterans with chronic hepatitis C. Am J Gastroenterol 2002; 97:2640-2646
20. Rosenberg SD, Swanson JW, Wolford GL, et al: The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv 2003; 54:827-835
21. Lee KC, Lim WW, Lee SS: High prevalence of HCV in a cohort of injectors on methadone-substitution treatment. J Clin Virol 2008; 41:297-300
22. Foster GR, Goldin RD, Thomas HC: Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 1998; 27:209-212
23. Sheppard K, Hubbert A: The patient experience of treatment for hepatitis C. Gastroenterol Nurs 2006; 29:309-315
24. Knott A, Dieperink E, Willenbring ML, et al: Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101:2254-2262
25. Saunders JC, Cookman CA: A clarified conceptual meaning of hepatitis C-related depression. Gastroenterol Nurs 2005; 28:123-129; quiz: 130-121
26. Sutton R, Treloar C: Chronic illness experiences, clinical markers, and living with hepatitis C. J Health Psychol 2007; 12:330-340
27. Fraser S, Treloar C: "Spoiled identity" in hepatitis C infection: the binary logic of despair. Critical Public Health 2006; 16:99-110
28. Asbring P: Chronic illness, a disruption in life: identity-transformation among women with chronic fatigue syndrome and fibromyalgia. J Adv Nurs 2001; 34:312-319
29. Zweben JE: Hepatitis C: education and counseling issues. J Addict Dis 2001; 20:33-42
30. Kralik D, Koch T, Price K, et al: Chronic illness self-management: taking action to create order. J Clin Nurs 2004; 13:259-267
31. Hicks D, Rundell J: HIV testing and counseling. Int Rev of Psychiatry 1996; 8:177-184
32. Munoz-Plaza C, Strauss SM, Astone JM, et al: HCV (Hepatitis C virus) pre-test and post-test counseling services at drug treatment programs: missed opportunities for primary prevention. Contemporary Drug Problems 2005; 32:655-675
33. Stein MD, Maksad J, Clarke J: Hepatitis C disease among injection drug users: knowledge, perceived risk, and willingness to receive treatment. Drug Alcohol Depend 2001; 61:211-215
34. Strauss SM, Astone JM, Hagan H, et al: The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units. J Urban Health 2004; 81:38-47
35. Bourbeau J, Nault D, Dang-Tan T: Self-management and behaviour modification in COPD. Patient Educ Couns 2004; 52:271-277
36. Devine EC, Reifschneider E: A meta-analysis of the effects of psychoeducational care in adults with hypertension. Nurs Res 1995; 44:237-245
37. Ganz PA: Patient education as a moderator of psychological distress. J Psychosocial Oncol 1988; 6:181-197
38. Kizer EE, Whitehead AJ, Indest DW, et al: Efficacy of group education in veterans with hepatitis C. Federal Practitioner 2006;23:50-57
39. Carrico AW, Antoni MH, Duran RE, et al: Reductions in depressed mood and denial coping during cognitive-behavioral stress management with HIV-positive gay men treated with HAART. Ann Behav Med 2006; 31:155-164
40. Carrico AW, Antoni MH, Weaver KE, et al: Cognitive-behavioural stress management with HIV-positive homosexual men: mechanisms of sustained reductions in depressive symptoms. Chronic Illness 2005; 1:207-215
41. Richmond J, Dunning R, Desmond P: Hepatitis C: a medical and social diagnosis. Aust Nurs J 2004:1-4
42. Zickmund S, Ho EY, Masuda M, et al: "They treated me like a leper:" stigmatization and the quality of life of patients with hepatitis C. J Gen Intern Med 2003; 18:835-844
43. Paterson BL, Backmund M, Hirsch G, et al: The depiction of stig- matization in research about hepatitis C. Int J Drug Policy 2007;18:364-373
44. Golden J, Conroy RM, O'Dwyer AM, et al: Illness-related stigma, mood, and adjustment to illness in persons with hepatitis C. Soc Sci Med 2006; 63:3188-3198
45. Hajela R: The stigma facing drug abusers impedes treatment. CMAJ 1998; 158:1265-1266
46. Chesney MA, Smith AW: Critical delays in HIV testing and care: the potential role of stigma. American Behavioral Scientist 1999; 42:1162-1174
47. Buseh AG, Stevens PE: Constrained but not determined by stigma: resistance by African American women living with HIV. Women Health 2006; 44:1-18
48. Rhodes JE: Family, friends, and community: the role of social support in promoting health, in Clinical Handbook of Health Psychology. Edited by Knight PCS. Seattle, WA, Hogrefe & Huber, 1998, pp 481-493
49. Larson DB, Larson SS, Johnson BR: Families, relationships, and health, in Behavior and Medicine. Edited by Wedding D. Seattle, WA, Hogrefe & Huber, 2001, pp 13-30
50. Grundy G, Beeching N: Understanding social stigma in women with hepatitis C. Nurs Stand 2004; 19:35-39
51. Robinson A: Meeting the psychological needs of hepatitis C patients on combination therapy. Issues in Interdisciplinary Care 2001;177-183
52. Terrault NA: Sexual activity as a risk factor for hepatitis C. Hepatology 2002; 36:S99-S105
53. Cormier M: The role of hepatitis C support groups. Gastroenterol Nurs 2005; 28:S4-S9
54. Jessop AB, Cohen C, Burke MM, et al: Hepatitis support groups: meeting the information and support needs of hepatitis patients. Gastroenterol Nurs 2004; 27:163-169
55. Grebely J, Genoway K, Khara M, et al: Treatment uptake and outcomes among current and former injection drug users receiving directly-observed therapy within a multidisciplinary group model for the treatment of hepatitis C virus infection. Int J Drug Policy 2007; 18:437-443
56. Sylvestre DL, Zweben JE: Integrating HCV services for drug- users: a model to improve engagement and outcomes. Int J Drug Policy 2007; 18:406-410
57. Dept. of Veterans Affairs: National Hepatitis C Program. accessed Feb 1, 2008, from www.hepatitis.va.gov
58. Maunder RG, Hunter JJ, Feinman SV: Interferon treatmentofhep- atitis C associated with symptoms of PTSD. Psychosomatics 1998; 39:461-464
59. Dieperink E, Ho SB, Thuras P, et al: A prospective study of neu- ropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44:104-112
60. Bianchi G, Loguercio C, Sgarbi D, et al: Reduced quality of life in patients with chronic hepatitis C: effects of interferon treatment. Dig Liver Dis 2000; 32:398-405
61. Hunt CM, Dominitz JA, Bute BP, et al: Effect of interferon-alpha treatment of chronic hepatitis C on health-related quality of life. Dig Dis Sci 1997; 42:2482-2486
62. Rifai MA, Indest D, Loftis J, et al: Psychiatric management of the hepatitis C patient. Curr Treat Options Gastroenterol2006; 9:508-519
63. Silberbogen AK, Mori DL, Sogg S: The Structured Interview for the Treatment of the Hepatitis C Virus (HCV-SIT). Journal of Clinical Psychology in Medical Settings 2005; 12:57-69
64. Loftis JM, Hauser P: The phenomenology and treatment of inter- feron-induced depression. J Affect Disord 2004; 82:175-190
65. Morasco BJ, Rifai MA, Loftis JM, et al: A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. J Affect Disord 2007; 103:83-90
66. Beck AT, Ward CH, Mendelson M, et al: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:561-571
67. Lehman CL: Hepatitis C in veterans: the role of psychology in a multidisciplinary clinic. Health Psychol 2001:17-21
68. Renault PF, Hoofnagle JH, Park Y, et al: Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577-1580
69. McHutchison JG, Manns M, Patel K, et al: Adherence to combination therapy enhances sustained response in genotype-1-in- fected patients with chronic hepatitis C. Gastroenterology 2002; 123:1061-1069
70. O'Donohue WT, Levensky ER (eds): Promoting Treatment Adherence: A Practical Handbook for Health Care Providers. Thousand Oaks, CA, Sage, 2006
71. Schiff ER: The alcoholic patient with hepatitis C virus infection. Am J Med 1999; 107:95S-99S
72. Poschl G, Seitz HK: Alcohol and cancer. Alcohol Alcohol 2004; 39:155-165
73. Hezode C, Lonjon I, Roudot-Thoraval F, et al: Impact ofmoderate alcohol consumption on histological activity and fibrosis in patients with chronic hepatitis C and specific influence of steatosis: a prospective study. Aliment Pharmacol Ther 2003; 17:1031-1037
74. Zarski JP, McHutchison J, Bronowicki JP, et al: Rate of natural disease progression in patients with chronic hepatitis C. J Hepatol 2003; 38:307-314
75. Harris DR, Gonin R, Alter HJ, et al: The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse. Ann Intern Med 2001; 134:120-124
76. Yee HS, Currie SL, Darling JM, et al: Management and treatment of hepatitis C viral infection: recommendations from the VA Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol 2006; 101:2360-2378
77. Pessione F, Degos F, Marcellin P, et al: Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C. Hepatology 1998; 27:1717-1722
78. Schiff ER, Ozden N: Hepatitis C and alcohol. Alcohol Res Health 2003; 27:232-239
79. Seeff LB, Hoofnagle JH: Appendix: The NIH Consensus Development Conference Management of Hepatitis C, 2002. Clin Liver Dis 2003; 7:261-287
80. Screening and Behavioral Counseling Interventions in Primary Care to Reduce Alcohol Misuse: Recommendation Statement. Am Fam Physician 2004; 70:353-358
81. Miller WR, Rollnick S: Motivational Interviewing. New York, Guilford, 1991
82. Bohn MJ, Babor TF, Kranzler HR: The Alcohol Use Disorders IDentification test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol 1995; 56:423-432
83. DiClemente CC, Carbonari JP, Montgomery RP, et al: The Alcohol Abstinence Self-Efficacy Scale. J Stud Alcohol 1994; 55:141-148
84. Rifai MA, Moles JK, Lehman LP, et al: Hepatitis C screening and treatment outcomes in patients with substance use/dependence disorders. Psychosomatics 2006; 47:112-121
85. Hezode C, Lonjon I, Roudot-Thoraval F, et al: Impact of smoking on histological liver lesions in chronic hepatitis C. Gut 2003; 52:126-129
86. Fujita Y, Shibata A, Ogimoto I, et al: The effect of interaction between hepatitis C virus and cigarette smoking on the risk of hepatocellular carcinoma. Br J Cancer 2006; 94:737-739
87. Tanaka K, Tsuji I, Wakai K, et al: Cigarette smoking and liver cancer risk: an evaluation based on a systematic review of epidemiologic evidence among Japanese. Jpn J Clin Oncol 2006; 36:445-456
88. El-Zayadi A, Selim O, Hamdy H, et al: Impact of cigarette smoking on response to interferon therapy in chronic hepatitis C Egyptian patients. World J Gastroenterol 2004; 10:2963-2966
89. Balfour L, Cooper C, Kowal J, et al: Depression and cigarette smoking independently relate to reduced health-related quality of life among Canadians living with hepatitis C. Can J Gastroenterol 2006; 20:81-86
90. Fiore MC, Cohen SJ: Treating Tobacco Use and Dependence: Quick Reference Guide for Clinicians. Rockville, MD, U.S. Dept. of Health and Human Services, Public Health Service, 2000
91. Alberino F, Gatta A, Amodio P, et al: Nutrition and survival in patients with liver cirrhosis. Nutrition 2001; 17:445-450
92. Marsano L, McClain CJ: Nutrition and alcoholic liver disease. J Parenter Enteral Nutr 1991; 15:337-344
93. Corrao G, Ferrari PA, Galatola G: Exploring the role of diet in modifying the effect of known disease determinants: application to risk factors of liver cirrhosis. Am J Epidemiol 1995; 142:1136-1146
94. Corrao G, Zambon A, Bagnardi V, et al: Nutrient intake, nutritional patterns, and the risk of liver cirrhosis: an explorative case- control study. Eur J Epidemiol 2004; 19:861-869
95. Manguso F, D'Ambra G, Menchise A, et al: Effects of an appropriate oral diet on the nutritional status of patients with HCV- related liver cirrhosis: a prospective study. Clin Nutr 2005; 24:751-759
96. Gapinski MA, Zucker DM: Factors influencing the development of a hepatitis C exercise protocol: a literature review. Gastroenterol Nurs 2005; 28:S10-S18
97. Painter P, Krasnoff J, Paul SM, et al: Physical activity and health- related quality of life in liver-transplant recipients. Liver Transpl 2001; 7:213-219
98. Adinolfi LE, Gambardella M, Andreana A, et al: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001; 33:1358-1364